AMArmelle Magot

Armelle Magot

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Armelle Magot has a total of 360 co-authors. Here are the top co-authors by number of shared publications:

  • Yann Péréon

    CHU Nantes Centre de Référence Maladies Neuromusculaires Rares AOC, Filnemus, Euro-NMD, University Hospital, France

    13 shared publications
  • Claire Lefeuvre

    Nord‐Est‐Ile‐de‐France Neuromuscular Reference Center, FHU, PHENIX Garches France

    5 shared publications
  • Françoise Bouhour

    ENMG Department, Referral Center for Neuromuscular Diseases Hôpital Neurologique P Wertheimer, Hospices Civils de Lyon Lyon France

    5 shared publications
  • Marco Spinazzi

    Neuromuscular Reference Center, Department of Neurology University Hospital Angers France

    5 shared publications
  • Nadjib Taouagh

    Centre de Référence Des Maladies NeuroMusculaires Nord – Est – Ile-de-France, Filnemus, Garches, France

    5 shared publications
  • Sandra Mercier

    CHU Nantes, Service de Génétique Médicale, Nantes, France

    5 shared publications

Latest Publications

  • Rituximab With or Without Chemotherapy for Anti‐ MAG Neuropathy: A Retrospective Multicenter Real‐World Study

    by Emilien Delmont, Pascal Cintas, Céline Tard, José Boucraut, Laurent Magy, Simon Frachet, Céline Labeyrie, Andoni Echaniz‐Laguna, Nicolas Noel, Juliette Svahn, et al.

    Background and Aims: In anti‐myelin‐associated glycoprotein (MAG) neuropathy, the efficacy of rituximab (RTX) is not demonstrated in randomized controlled trials. Combinations of RTX with conventional chemotherapy (immunochemotherapy, ICT) may provide potential benefit, but systematic evaluations are lacking. We aimed to compare the efficacy and safety of RTX and ICT in a multicenter retrospective real‐world cohort. Methods: Patients with anti‐MAG antibody titers > 10 000 Buhlmann titer units (BTUs) were included. Treatment response was defined as an improvement of ≥ 1 point in the Overall Neuropathy Limitation Scale (ONLS) compared to baseline. Propensity score matching was used to account for differences in baseline characteristics between treatment groups. Results: A total of 230 patients were included: 150 received RTX and 80 received ICT. Mean follow‐up was 4 years (range, 1–20 years). One year after treatment, clinical improvement occurred in 61/147 (41%) patients treated with RTX and 39/78 (50%) treated with ICT (OR = 1.4 [0.8–2.5] p = 0.3). At last follow‐up, clinical improvement occurred in 55/150 (37%) patients treated with RTX and 31/80 (39%) treated with ICT (OR = 1.1 [0.6–1.9] p = 0.8). Propensity score matching yielded similar results. Among ICT regimens, dexamethasone–RTX–cyclophosphamide was associated with the highest response rate. RTX induction, 1 g days 1 and 15, seemed superior to four‐weekly infusions. Adverse events were more frequent with ICT than with RTX (28% vs. 15%; OR = 2.20 [1.07–4.54], p = 0.02). Interpretation: In this cohort, adding chemotherapy to RTX was not associated with greater long‐term improvement, despite a higher rate of adverse events. Prospective controlled studies are needed.

  • Open Access

    Real‐Life Effectiveness After Switching to Avalglucosidase Alfa in Late‐Onset Pompe Disease Patients Worsening on Alglucosidase Alfa Therapy: A French Cohort Study

    by Céline Tard, Sabrina Sacconi, Nadjib Taouagh, Françoise Bouhour, Maud Michaud, Stephane Beltran, Maxime Fournier, Florence Demurger, Emmeline Lagrange, Sylvain Nollet, et al.

    Late‐onset Pompe disease (LOPD) is a progressive myopathy. Enzyme replacement therapy is effective, but long‐term outcomes vary. Avalglucosidase alfa, shown to be non‐inferior to alglucosidase alfa in a phase 3 trial, became available in France through compassionate use for patients with insufficient response to alglucosidase alfa. Methods: Data from the French Pompe registry were analyzed for patients who switched to avalglucosidase alfa with at least 1 year of follow‐up. Respiratory function (forced vital capacity, FVC) and motor function evaluated with gait performance (Six‐Minute Walk Test, 6MWT) were assessed before the switch, and one and 2 years after. Individual changes were compared using paired‐sample tests. Results: Forty‐seven adult patients were included. A stabilization of motor decline was observed: prior to switching, the 6MWT decreased by −27 m/year, whereas an improvement of +17 m/year was seen during the first year after the switch ( p = 0.001), followed by overall stability in the second year (−10 m/year, p = 0.280). Respiratory changes were not statistically significant: a decline of 60 mL/year before the switch versus 10 mL/year after 1 year ( p = 0.161), and 20 mL/year during the second year ( p = 0.346). Three patients died during follow‐up, with causes unrelated to the disease or treatment. Discussion: Gait deterioration halted during the first year after transitioning to avalglucosidase, with sustained stabilization thereafter, while respiratory parameters showed minimal change. For patients experiencing significant walking decline under alglucosidase alfa therapy, switching to avalglucosidase alfa resulted in disease stabilization, beginning with mild improvement in the first year and a return to pre‐switch baseline thereafter.

  • Limb Girdle Muscular Dystrophy Associated With TRIM32 Variants: A National Cohort Study

    by Alexandre Guérémy, V. Morel, T. Stojkovic, F. Bouhour, A. Nadaj Pakleza, J. Nectoux, E. Fortanier, A. Magot, S. Sacconi, B. Eymard, et al.

    Introduction/Aims: LGMDR8 is a very rare autosomal recessive limb‐girdle muscular dystrophy caused by variants in the TRIM32 gene. To date, 92 cases have been reported, mainly in the Hutterite population with a founder effect. This study aimed to describe a cohort of European origin and to investigate genotype–phenotype correlations. Methods: We conducted a retrospective, multicenter study of 14 French patients with genetically confirmed LGMDR8. Clinical, histological, electrodiagnostic, imaging, and genetic data were collected and compared with those from previously published cases. Results: Patients showed a slowly progressive disease course, with a mean age at onset of 25.1 years (range 7.5–40.0). The main presenting symptom was proximal lower limb weakness ( n = 13). At last follow‐up, all patients had proximal lower limb weakness, 10/14 had upper limb involvement, and 10/14 had distal lower limb weakness. Six patients lost ambulation (mean disease duration: 27.3 years). No cardiac or respiratory involvement was observed. Mean creatine kinase levels were mildly elevated (4.5× upper limit of normal). Muscle biopsies exhibited dystrophic features. Ragged‐red and COX‐negative fibers were observed in two patients. Muscle magnetic resonance imaging revealed symmetrical involvement predominantly affecting posterior thigh muscles. Fourteen distinct pathogenic variants were identified, including eight new ones. Six variants were located in the C‐terminal domain. LGMDR8 was estimated to account for 0.9% of the LGMD cases in France. No clear genotype–phenotype correlation was found. Discussion: LGMDR8 is very rare in non‐Hutterite patients. Age of onset is highly variable. Variants are distributed across most protein domains and did not predict clinical severity.

  • Open Access

    Causes of Death and Comorbidities in Adult Patients With Late‐Onset Pompe Disease: A French Pompe Registry Retrospective Study

    by Diana Maria Chitimus, Céline Tard, Maxime Fournier, Françoise Bouhour, Anthony Béhin, Emmanuelle Salort‐Campana, Emmeline Lagrange, Anne‐Laure Kaminsky, Armelle Magot, Stéphane Beltran, et al.

    Background and Objectives: Mortality in Late‐Onset Pompe Disease (LOPD) has been associated with the rapid progression of respiratory and motor impairment. However, an in‐depth approach to the exact causes of death in these patients is still lacking. Methods: In this retrospective cohort study, we analyzed the cause of death and the comorbidities of all deceased patients from the French Late‐Onset Pompe Disease registry. Results: By the time of the last extraction, 60 patients diagnosed with LOPD and monitored were registered as deceased in the French national registry, out of a total of 260 patients included. The median age of death was 70.5 years, while the median age of diagnosis was 58 years. The causes of death were divided into disease‐related, accounting for 46.6% of deaths, and non‐disease‐related, comprising 28.3% of total deaths. Fifteen patients (25%) died of an unknown cause. The most frequent etiology of disease‐related death was respiratory failure ( n = 14), while for the non‐disease‐related group, malignant neoplasm was the most common ( n = 8). Patients in the non‐disease‐related death group had significantly higher forced vital capacity (FVC) values compared to those in the disease‐related death group (54.7% vs. 38%). Treatment‐wise, the median period elapsed from diagnosis to ERT introduction was higher in the disease‐related group. Discussion: This is the first study to focus on the specific causes of death of LOPD patients. The majority of the LOPD deaths in the French registry were attributed to respiratory failure and malignant neoplasms.


  • Etiologic Diagnosis of Neuropathies Based on First‐Line Screening of TTR Gene Mutations

    by Armelle Magot, Maud Lepetit, Steeve Genestet, Jean‐Baptiste Noury, Yolaine Ollivier, Pascal Lejeune, Lucie Metzger, Stephane Beltran, Julien Cassereau, Morgane Pihan, et al.

    Background: Hereditary amyloid transthyretin (ATTRv) is caused by TTR gene mutations, which lead to multisystem amyloid deposits. A misdiagnosis is common, which delays treatment. We assessed the prevalence of TTR mutations in patients with neuropathy of unknown cause at the first stage of assessment.Methods: This prospective study, conducted in western France, assessed patients with neuropathy aged 18–90 years. We excluded individuals with known causes or prior screening of TTR mutations. Genetic analyses of TTR mutations were done using Sanger sequencing. Clinical, biochemical, and electrophysiological data were collected. Statistical analyses estimated the prevalence of TTR amyloidosis in this cohort.Results: Among 400 patients, four (1%) were identified as having a heterozygous TTR mutation. The mean age of these patients with a TTR mutation was 75 years, with a mean duration of neuropathy of 2.5 years. The initial symptoms varied, with one patient experiencing mixed sensory impairment, another with motor and sensory issues, one with purely motor symptoms, and one with small‐fiber sensory impairment. Notably, none had cardiological or renal impairments, and all exhibited sensorimotor neuropathy upon electromyography. Three patients had an axonal profile, and one showed demyelinating neuropathy, which highlighted the diagnostic challenges.Interpretation: We identified a 1% prevalence of TTR mutations, which is lower than that reported previously, and highlights the influence of selective inclusion criteria on such estimates. Our data emphasize the need for early detection because patients frequently lack red‐flag symptoms. Ultimately, early screening allows for prompt management and minimizes long‐term complications in individuals with unexplained neuropathy.Trial Registration: ClinicalTrials.Gov Identifier: NCT03190577.

  • Open Access

    Spinal muscular atrophy is also a disorder of spermatogenesis

    by Armelle Magot, Arnaud Reignier, Olivier Binois, Anne Laure Bedat-Millet, Jean-Baptiste Davion, Louise Debergé, Karima Ghorab, Lucie Guyant, Émilie Laheranne, Pascal Laforet, et al.

    Background: Spinal muscular atrophy (SMA) patients benefit from pre-mRNA splicing modifiers targeting the SMN2 gene, which aims to increase functional SMN production. The animal toxicity affecting spermatogenesis associated with one such treatment raised questions about male SMA patients’ spermatogenesis. Methods: This descriptive, cross-sectional study was conducted from June 2022 to July 2023. The study involved adult male patients with genetically confirmed SMA type 2 (SMA2) or SMA3 from 13 French neuromuscular centers. The patients’ general data, motor severity, urological history, exposure to certain factors, parenthood, and spermogram results were obtained. All patients were enrolled prior to exposure to risdiplam. Findings: Sixty-eight patients were enrolled ( 36 SMA2 and 32 SMA3 patients). Forty-one patients had fertility data (parenthood history and spermogram analyses) and underwent 33 spermograms. Fertility disorders were identified in 27 of the 41 patients (65·9%, 95%CI 51·3–80·4%) in particular SMA2 patients: 19 cases (90.5%, CI 77·9–100%) (SMA3: 8 cases (40%, CI 18·5–61·5%). Among the patients with available spermograms, 81% (27/33) had abnormal sperm concentration; 30% presented azoospermia. These abnormalities were significantly associated with SMA type (more prevalent in SMA2 patients, p < 0·001), disease motor severity, which included age at the loss of walking ability and wheelchair use duration (p < 0·001). The Motor Function Measure (MFM) determined that the sperm counts were also correlated with disease severity (p < 0·01). Interpretation: The fertility disorders were correlated with SMA severity and were particularly evident in SMA2 patients. In the latter, sperm concentration positively correlated with MFM. This study is the first one to link fertility disorders with spermogram abnormalities in SMA males. Understanding spermatogenesis in SMA is crucial, especially with new therapies such as risdiplam. Consequently, conducting systematic spermogram studies prior to SMA treatment is recommended.


  • Open Access

    Spinal muscular atrophy is also a disorder of spermatogenesis

    by Armelle Magot, Arnaud Reignier, Olivier Binois, Anne-Laure Bedat Millet, Jean-Baptiste Davion, Louise Deberge, Karima Ghorab, Lucie Guyant, Emilie Laheranne, Pascal Laforet, et al.

    Background Spinal muscular atrophy (SMA) patients benefit from pre-mRNA splicing modifiers targeting the SMN2 gene, which aims to increase functional SMN production. The animal toxicity affecting spermatogenesis associated with one such treatment raised questions about male SMA patients’ spermatogenesis. Methods This descriptive, cross-sectional study was conducted from June 2022 to July 2023. The study involved adult male patients with genetically confirmed SMA type 2 (SMA2) or SMA3 from 13 French neuromuscular centers. The patients’ general data, motor severity, urological history, exposure to certain factors, parenthood, and spermogram results were obtained. All patients were enrolled prior to exposure to risdiplam. Findings Sixty-eight patients were enrolled ( 36 SMA2 and 32 SMA3 patients). Forty-one patients had fertility data (parenthood history and spermogram analyses) and underwent 33 spermograms. Fertility disorders were identified in 27 of the 41 patients (65·9%, 95%CI: 51·3%–80·4%) in particular SMA2 patients: 19 cases (90.5%, CI: 77·9%-100%) (SMA3: 8 cases (40%, CI :18·5%-61·5%). Among the patients with available spermograms, 81% (27/33) had abnormal sperm concentration; 30% presented azoospermia. These abnormalities were significantly associated with SMA type (more prevalent in SMA2 patients, p < 0·001), disease motor severity, which included age at the loss of walking ability and wheelchair use duration (p < 0·001). The Motor Function Measure (MFM) determined that the sperm counts were also correlated with disease severity (p < 0·01). Interpretation The fertility disorders were correlated with SMA severity and were particularly evident in SMA2 patients. In the latter, sperm concentration positively correlated with MFM. This study is the first one to link fertility disorders with spermogram abnormalities in SMA males. Understanding spermatogenesis in SMA is crucial, especially with new therapies such as risdiplam. Consequently, conducting systematic spermogram studies prior to SMA treatment is recommended.

  • Open Access

    Neurosarcoidosis: Clinical, biological, and MRI presentation of central nervous system disease in a national multicenter cohort

    by Amélie Dos Santos, Edouard Courtin, Aurélie Ruet, Pierre Duffau, Guillaume Mathey, Ines Bekkour, Jonathan Ciron, Laure Michel, François Xavier Blanc, Jésus Aguilar, et al.

    Introduction: Neurosarcoidosis (NS) is a systemic inflammatory granulomatous disease affecting of patients with sarcoidosis. Its diagnosis is difficult as there is no specific test for it. Because of its rarity, the management of NS has so far only been described in case series and short retrospective cohorts. The objective of this study is description of the clinical, paraclinical presentation and the therapeutic management of central nervous system (CNS) involvement in NS patients in France.Methods: This multicenter, retrospective, observational study involved patients hospitalized between 2010 and 2019 with a diagnosis of sarcoidosis and CNS involvement.Results: We included 118 patients (38 with isolated NS, 80 with NS associated with systemic sarcoidosis). NS was the initial presentation in 78% of patients, with cranial nerve involvement (36%), medullary symptoms (23%), and seizures (21%). Twenty‐one percent of the patients had already been diagnosed with systemic sarcoidosis. The most frequent biological abnormality was lymphopenia (62.5%), while angiotensin‐converting enzyme was increased in 21%. Meningitis was present in 45% and hyperproteinorachia in 69.5% of cases. MRI mainly revealed white matter abnormalities and leptomeningeal enhancement (34%). Corticosteroids were the most useful treatment, and immunosuppressive agents were used in steroid‐resistant patients and to limit side effects. Methotrexate, cyclophosphamide, and anti‐TNFα were also used, exhibiting good efficacy.Conclusions: This cohort contributes to a better understanding of the clinical phenotype and associated imaging and biological abnormalities. Sharing of clinical, biological, and imaging data, as well as the therapeutic responses, of patients with NS helps to better understand and manage this disease that affects a small number of patients per center. A database project could be implemented in the future to enable this.


  • Open Access

    Bulbar muscle impairment in patients with late onset Pompe disease: Insight from the French Pompe registry

    by Emilie Retailleau, Claire Lefeuvre, Marie De Antonio, Françoise Bouhour, Celine Tard, Emmanuelle Salort‐Campana, Emmeline Lagrange, Anthony Béhin, Guilhem Solé, Jean‐Baptiste Noury, et al.

    Background and purpose: Late onset Pompe disease (LOPD) is a rare neuromuscular disorder caused by a deficit in acid alpha‐glucosidase. Macroglossia and swallowing disorders have already been reported, but no study has focused yet on its frequency and functional impact on patients' daily life.Methods: We reviewed 100 adult LOPD patients followed in 17 hospitals in France included in the French national Pompe disease registry. The Swallowing Quality of Life Questionnaire and the Sydney Swallow Questionnaire were completed by patients, and a specialist carried out a medical examination focused on swallowing and assigned a Salassa score to each patient. Respiratory and motor functions were also recorded. Subgroup analysis compared patients with and without swallowing difficulties based on Salassa score.Results: Thirty‐two percent of patients presented with swallowing difficulties, often mild but sometimes severe enough to require percutaneous endoscopic gastrostomy (1%). Daily dysphagia was reported for 20% of our patients and aspirations for 18%; 9.5% were unable to eat away from home. Macroglossia was described in 18% of our patients, and 11% had lingual atrophy. Only 15% of patients presenting with swallowing disorders were followed by a speech therapist. Swallowing difficulties were significantly associated with macroglossia (p = 0.015), longer duration of illness (p = 0.032), and a lower body mass index (p = 0.047).Conclusions: Swallowing difficulties in LOPD are common and have significant functional impact. Increased awareness by physicians of these symptoms with systematic examination of the tongue and questions about swallowing can lead to appropriate multidisciplinary care with a speech therapist and dietitian if needed.


  • Expanding the Spectrum of Congenital Myopathy Linked to Variants in the MYBPC1 Gene

    by Pierre-Louis Lanvin, Dong Li, Solène Conrad, Armelle Magot, Xavier Micaelli, Yann Péréon, Marie Vincent, Bertrand Isidor, Damien Sternberg, Elizabeth M. McCormick, et al.

    ObjectivesHeterozygous missense variants in MYBPC1 have been recently identified in 13 patients from 6 families with congenital myopathy with tremor. All the patients had mild skeletal myopathy invariably associated with a distinctive myogenic tremor and ...